TD Cowen Lifts REGN Target to $980 as Options Turn Bullish Before Earnings
Nine days before Q3 results, Regeneron Pharmaceuticals is collecting analyst upgrades, shedding short interest, and showing the most call-heavy options positioning in weeks. TD Cowen's Tyler Van Buren lifted his price…